MARKET

MDCX

MDCX

Medicus Pharma Ltd
NASDAQ
0.4580
+0.0130
+2.92%
After Hours: 0.4673 +0.0093 +2.03% 19:52 06/26 EDT
OPEN
0.4600
PREV CLOSE
0.4450
HIGH
0.4798
LOW
0.4401
VOLUME
1.87M
TURNOVER
--
52 WEEK HIGH
3.690
52 WEEK LOW
0.2500
MARKET CAP
25.95M
P/E (TTM)
-0.1714
1D
5D
1M
3M
1Y
5Y
1D
Medicus Pharma to present at Bio International Conference, outlining SkinJect registrational plan
PUBT · 06/22 11:30
Weekly Report: what happened at MDCX last week (0615-0619)?
Weekly Report · 06/22 10:01
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
Barchart · 06/22 06:30
New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA
Barchart · 06/20 12:30
Medicus submits SkinJect Rare Pediatric Disease Designation request to FDA
TipRanks · 06/15 11:51
Medicus Pharma submits FDA rare pediatric disease designation request for SkinJect in Gorlin syndrome
PUBT · 06/15 11:30
MEDICUS PHARMA ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION (FDA) SUBMISSION OF RARE PEDIATRIC DISEASE DESIGNATION REQUEST FOR SKINJECT® IN GORLIN SYNDROME
Reuters · 06/15 11:30
Weekly Report: what happened at MDCX last week (0608-0612)?
Weekly Report · 06/15 10:02
More
About MDCX
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.

Webull offers Medicus Pharma Ltd stock information, including NASDAQ: MDCX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDCX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDCX stock methods without spending real money on the virtual paper trading platform.